Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.

Nagy B., Zelei T., Vellekoop H., Huygens S., Versteegh M., Mölken MR-V., Koleva-Kolarova R., Tsiachristas A., Wordsworth S., Szilberhorn L.

Background: The HEcoPerMed consortium developed a methodological guidance for the harmonization and improvement of economic evaluations in personalized medicine. Materials & methods: In three therapeutic areas, health economic models were developed to scrutinize the recommendations of the guidance. Results: Altogether, 20 of the 23 recommendations of the guidance were addressed by the models. Seven recommendations were applied in all studies, six in two of the studies and seven in one of the studies. Recommendations with an essential role on the final conclusions of the analyses were identified in each study. Conclusion: The guidance was found to be best used as a tool to identify and prioritize issues, verify solutions and justify decisions during the economic analysis of personalized interventions.

DOI

10.2217/pme-2023-0040

Type

Journal article

Journal

Per Med

Publication Date

11/09/2023

Keywords

cost–effectiveness, economic evaluation, genetic testing, guidance, modeling, personalized medicine, recommendations

Permalink Original publication